Clinical Trial Update: Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating nivolumab in combination with 5-azacytidine for childhood relapsed/refractory acute myeloid leukemia (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• 5-Azacytidine (5-azacytidine)
• nivolumab (nivolumab)

Snippet

Sponsor: Therapeutic Advances in Childhood Leukemia Consortium | Conditions: AML, Childhood | Phase 1, Phase 2 | Status: UNKNOWN